Evotec (NASDAQ:EVO) Announces Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Evotec (NASDAQ:EVO) released its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.25), FiscalAI reports. The company had revenue of $181.32 million for the quarter, compared to analysts’ expectations of $239.17 million. Evotec had a negative net margin of 13.13% and a negative return on equity of 12.40%.

Here are the key takeaways from Evotec’s conference call:

• Evotec has moved Horizon from announcement into implementation, recording EUR 75m of restructuring provisions in Q1 and targeting ~EUR 75m of structural run‑rate savings by end‑2027 (20–30% expected to materialize in 2026).
• Q1 revenue was EUR 156.6m and adjusted EBITDA was negative EUR 21.9m, with management citing a non‑recurring $25m Sandoz license, FX headwinds and D&PD softness; the company reiterated full‑year 2026 guidance (EUR 700–780m revenue; EUR 0–40m adj. EBITDA).
• Leadership was strengthened with appointments of Claire Hinshelwood as CFO, Ingrid Muller as COO and Ashiq H. Khan as CCO to drive financial continuity, operational delivery and commercial execution during the transformation.
• Early commercial indicators improved: proposal activity reached a 12‑month high, negative change orders declined, proposal turnaround times shortened and net sales orders were up ~15% year‑on‑year, supporting management’s expectation of H2 recovery.
• Liquidity remains solid at EUR 444.8m (net cash position) and management expects ~USD 100m of gross proceeds in Q2 from the Gilead acquisition of Tubulis, which will further bolster cash resources.

Evotec Stock Up 1.3%

NASDAQ EVO traded up $0.04 during trading on Wednesday, hitting $3.24. 139,333 shares of the stock traded hands, compared to its average volume of 109,128. The firm has a 50-day simple moving average of $2.85 and a 200-day simple moving average of $3.22. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.99 and a current ratio of 2.07. Evotec has a 12-month low of $2.31 and a 12-month high of $4.80.

Hedge Funds Weigh In On Evotec

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after purchasing an additional 367,545 shares during the last quarter. Jane Street Group LLC bought a new position in Evotec during the fourth quarter valued at $565,000. Millennium Management LLC bought a new stake in Evotec during the fourth quarter worth approximately $317,000. Citadel Advisors LLC increased its stake in Evotec by 186.1% during the third quarter. Citadel Advisors LLC now owns 96,045 shares of the company’s stock worth $349,000 after acquiring an additional 62,471 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new stake in Evotec during the fourth quarter worth approximately $158,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on EVO shares. Berenberg Bank started coverage on Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. HC Wainwright started coverage on Evotec in a research report on Wednesday, April 15th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.00.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.